Back to search results

Study of GHZ339 for Moderate to Severe Atopic Dermatitis

This study is testing an investigational drug called GHZ339 for people with moderate to severe atopic dermatitis (AD), a chronic skin condition. Researchers want to see how well GHZ339 works and if it's safe compared to a placebo (an inactive substance). You may be able to join if you are 18 to 100 years old, have been diagnosed with AD for at least one year, and have moderate to severe AD. The main goal is to see how much your Eczema Area and Severity Index (EASI) score, which measures the extent and severity of your eczema, changes after 16 weeks. The current status of this study is unclear.

Study design
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study with a planned enrollment of 224 participants. Participants will be randomly assigned to receive GHZ339 at different doses or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 16, indicating follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06947993

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Recruiting
PHASE2Ages 18+InterventionalTreatment
Novartis Pharmaceuticals
~224 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:GHZ339Placebo

At a glance

Recruiting sites
69 of 105 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16
Measured over Baseline, Week 16

Conditions

Atopic Dermatitis

Explore related trials

Atopic Dermatitis

Where it's being run

105 sites across 52 states
France7
Germany7
Spain6
California5
Texas5
Czechia5
Slovakia5
Poland4

Who to contact

Novartis Pharmaceuticals
[email protected]
1-888-669-6682
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able and willing to sign the informed consent (IC)
Patients with a diagnosis of AD and onset of disease for at least 1 year
Moderate to severe AD

Exclusion

Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
Participant with any other active inflammatory skin disease
Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma)

What this trial measures

  • Change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16Baseline, Week 16

    EASI will be used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.